NCT05275998View on ClinicalTrials.gov

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

November 20, 2024

Study Completion Date

November 20, 2024

Conditions
HIV-1-infection
Interventions
DRUG

TMB-365/TMB-380

Monoclonal antibodies to be given intravenously

Trial Locations (6)

32803

Orlando Immunology Center, Orlando

33316

CAN Community Health, Fort Lauderdale

34892

Midway Immunology and Research Center, Ft. Pierce

75246

North Texas Infectious Disease Consultants, Dallas

77098

Crofoot Research Center, Inc., Houston

94115

Quest Clinical Research, San Francisco

All Listed Sponsors
lead

TaiMed Biologics Inc.

INDUSTRY